Walking Fish Therapeutics
Rapidly advancing cell-based therapeutics to treat serious diseases, concentrating on oncology and regenerative therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | $73.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Walking Fish Therapeutics (WFT) is a biotechnology startup that specializes in B cell engineering. The company has developed a unique platform that leverages the protein production capabilities of B cells to create therapeutics for a range of medical conditions. These include oncology, regenerative medicine, autoimmune disease, and recombinant antibody production.
The company's business model revolves around the production and commercialization of these therapeutic proteins. By engineering B cells to produce specific proteins, Walking Fish can create targeted treatments for various diseases. This includes engineered antibodies for infectious diseases, replacement proteins for deficiency diseases, immune-inhibitory proteins for autoimmune diseases, and regenerative proteins.
Walking Fish operates in the biotechnology market, serving clients in the healthcare sector. These clients can include hospitals, clinics, and other healthcare providers, as well as pharmaceutical companies that may be interested in the company's innovative protein therapies.
The company's revenue is likely generated through the sale of these therapies, as well as through partnerships and collaborations with other entities in the healthcare and pharmaceutical sectors. Walking Fish's business model is supported by a team of cell engineering, manufacturing, and clinical experts, led by repeat entrepreneur and CEO Lewis "Rusty" Williams.
In summary, Walking Fish Therapeutics is a pioneering biotech startup that harnesses the power of B cells to create innovative protein therapies for a range of medical conditions.
Keywords: Biotechnology, B cell engineering, Protein therapies, Oncology, Regenerative medicine, Autoimmune disease, Recombinant antibody production, Healthcare sector, Pharmaceutical partnerships, Entrepreneurial leadership.